Literature DB >> 3972708

Sulfadiazine-induced allergy in six Doberman pinschers.

U Giger, L L Werner, N J Millichamp, N T Gorman.   

Abstract

Treatment with sulfadiazine-trimethoprim caused serious, but reversible, allergic drug reactions in 6 Doberman Pinschers 10 to 21 days after the first drug exposure and/or within 1 hour to 10 days after reexposure. Nonseptic polyarthritis was found in all dogs. Glomerulonephropathy, focal retinitis, polymyositis, skin rash, fever, anemia, leukopenia, and thrombocytopenia were found in some dogs. These clinical abnormalities were typical of an immune-mediated vasculitis and mimicked other immune-mediated disorders. In a drug challenge study, 1 dog was given sulfadiazine and trimethoprim separately. Administration of trimethoprim alone did not result in any abnormalities; however, exposure to sulfadiazine caused recurrence of the polyarthritis, glomerulonephropathy, and focal retinitis within 5 days, suggesting that sulfadiazine likely was the offending agent in all cases. In addition, during the sulfadiazine reexposure, marked complement activation was documented at the time clinical signs were apparent, supporting the suggestion that sulfadiazine caused an immune complex disease (type-III hypersensitivity reaction). Since all dogs were of the same breed, a genetic predisposition of some Doberman Pinschers to react adversely to sulfadiazine was suspected.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3972708

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN: 0003-1488            Impact factor:   1.936


  11 in total

1.  N-acetyltransferases: pharmacogenetics and clinical consequences of polymorphic drug metabolism.

Authors:  S P Spielberg
Journal:  J Pharmacokinet Biopharm       Date:  1996-10

2.  Evaluation of polymorphisms in the sulfonamide detoxification genes CYB5A and CYB5R3 in dogs with sulfonamide hypersensitivity.

Authors:  J Funk-Keenan; J Sacco; Y Y Amos Wong; S Rasmussen; A Motsinger-Reif; L A Trepanier
Journal:  J Vet Intern Med       Date:  2012-07-21       Impact factor: 3.333

Review 3.  A review of immunologic diseases of the dog.

Authors:  N C Pedersen
Journal:  Vet Immunol Immunopathol       Date:  1999-08-02       Impact factor: 2.046

4.  An in vitro investigation of predisposition to sulphonamide idiosyncratic toxicity in dogs.

Authors:  A E Cribb; S P Spielberg
Journal:  Vet Res Commun       Date:  1990       Impact factor: 2.459

5.  Immune-mediated hemolytic anemia associated with trimethoprim-sulphamethoxazole administration in a horse.

Authors:  H L Thomas; M A Livesey
Journal:  Can Vet J       Date:  1998-03       Impact factor: 1.008

6.  A single-nucleotide polymorphism in the canine cytochrome b5 reductase (CYB5R3) gene is associated with sulfonamide hypersensitivity and is overrepresented in Doberman Pinschers.

Authors:  J M Reinhart; J Ekena; A C Cioffi; L A Trepanier
Journal:  J Vet Pharmacol Ther       Date:  2018-01-15       Impact factor: 1.786

7.  Canine immune-mediated polyarthritis: clinical and laboratory findings in 83 cases in western Canada (1991-2001).

Authors:  Jason W Stull; Michelle Evason; Anthony P Carr; Cheryl Waldner
Journal:  Can Vet J       Date:  2008-12       Impact factor: 1.008

8.  Short- and long-term cure rates of short-duration trimethoprim-sulfamethoxazole treatment in female dogs with uncomplicated bacterial cystitis.

Authors:  S Clare; F A Hartmann; M Jooss; E Bachar; Y Y Wong; L A Trepanier; K R Viviano
Journal:  J Vet Intern Med       Date:  2014-03-27       Impact factor: 3.333

9.  Utility of Urinary Markers in the Assessment of Renal Dysfunction in Familial Glomerulonephritis in Dobermann Dogs.

Authors:  Dagmara Winiarczyk; Łukasz Adaszek; Jacek Madany; Mateusz Winiarczyk; Stanisław Winiarczyk
Journal:  J Vet Res       Date:  2020-02-14       Impact factor: 1.744

Review 10.  Laboratory evaluation and interpretation of synovial fluid.

Authors:  Peter S MacWilliams; Kristen R Friedrichs
Journal:  Vet Clin North Am Small Anim Pract       Date:  2003-01       Impact factor: 2.093

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.